Novel radioligand therapy proven superior for metastatic prostate cancer patients

A novel prostate cancer treatment—225Ac-PSMA-617 radioligand therapy—has been shown to increase the progression free survival (PFS) and overall survival (OS) of metastatic castration-resistant prostate cancer (mCRPC) patients, according to research published by The Journal of Nuclear Medicine. Ninety-one percent of patients experienced a greater than 50% reduction of their initial PSA (prostate specific antigen) value after treatment with 225Ac-PSMA-617, resulting in a PFS of 22 months and an OS not yet reached at the conclusion of the study.
A novel prostate cancer treatment—225Ac-PSMA-617 radioligand therapy—has been shown to increase the progression free survival (PFS) and overall survival (OS) of metastatic castration-resistant prostate cancer (mCRPC) patients, according to research published by The Journal of Nuclear Medicine. Ninety-one percent of patients experienced a greater than 50% reduction of their initial PSA (prostate specific antigen) value after treatment with 225Ac-PSMA-617, resulting in a PFS of 22 months and an OS not yet reached at the conclusion of the study.